Veeva Systems Inc. — Form 10-Q Summary
Reporting period: Second quarter and first six months of fiscal 2022, ended July 31, 2021; comparisons are with the corresponding 2020 periods. Veeva provides cloud software, data, and services primarily to the life sciences industry. Amounts below are in U.S. dollars.
Key financial results
| Metric | Q2 FY2022 | Q2 FY2021 | Six months FY2022 | Six months FY2021 |
|---|---|---|---|---|
| Revenue | $455.6M (+29%) | $353.7M | $889.2M (+29%) | $690.8M |
| Subscription revenue | $366.4M (+29%) | $283.5M | $707.6M (+28%) | $553.7M |
| Professional services and other | $89.2M (+27%) | $70.2M | $181.6M (+33%) | $137.1M |
| Gross profit / margin | $333.5M / 73% | $256.5M / 73% | $650.9M / 73% | $498.7M / 72% |
| Operating income | $124.6M | $90.1M | $253.1M | $177.6M |
| Net income | $108.9M | $93.6M | $224.4M | $180.1M |
| Diluted EPS | $0.67 | $0.58 | $1.38 | $1.12 |
| Operating cash flow | $119.1M | $105.3M | $597.5M | $387.5M |
Financial position and material changes
- At July 31, 2021, cash and cash equivalents were $1.065B and short-term investments were $1.199B, totaling about $2.26B. Current assets were $2.632B versus current liabilities of $663M.
- The balance sheet reports no borrowings; lease liabilities totaled $58.7M. Deferred revenue was $558.7M, down from $617.0M at January 31, 2021.
- Revenue growth was broad-based. Q2 subscription revenue increased $52M from Vault and $31M from Commercial Cloud. Vault subscription revenue was $190.4M versus $138.7M a year earlier; Commercial Cloud was $176.1M versus $144.8M.
- Operating expenses rose 26% in Q2 to $208.9M, led by research and development, up 35% to $94.9M. Stock-based compensation was $62.4M in Q2 and $110.9M for the six-month period.
- For the six months, operating cash flow increased substantially year over year, principally due to higher sales and customer collections. The company said first-quarter cash flows are seasonally strongest and expects operating cash flow to be substantially lower in later quarters of this fiscal year.
- Investing cash outflow for the six months was $280.8M, primarily reflecting net purchases of short-term investments. Financing cash flow included $15.1M of taxes paid on RSU net share settlements, a practice begun in June 2021.
Outlook, commentary, and risks
- Management expects revenue growth rates to decline over time. No specific forward quarterly or full-year revenue or earnings guidance is stated in the provided filing text.
- Management expects operating expenses and stock-based compensation to increase as it invests in product development, sales, and services; R&D may rise as a percentage of revenue. Most employees received a 5% salary increase effective September 1, 2021.
- Remaining performance obligations for subscription services were approximately $1.197B at July 31, 2021; about 72% is expected to be recognized over the next 12 months.
- COVID-19’s financial impact had not been materially negative to date, but remained uncertain. Management noted potential benefits from accelerated digital adoption, alongside risks from customer constraints and changing work practices. It expects life sciences companies may reduce sales-representative headcount by roughly 10% over the next one to two years, potentially pressuring CRM-related demand.
- Material litigation includes disputes with IQVIA and Medidata. In the IQVIA OpenData/Network case, the company appealed discovery-sanctions rulings; outcome and potential loss could not be estimated. The Medidata matter had a trial date set for December 6, 2021; Veeva said it could not estimate potential loss.
- Other key risks include competition, reliance on Salesforce and third-party cloud infrastructure and data providers, cybersecurity and privacy obligations, customer concentration, and life-sciences industry consolidation. The company also became a Delaware public benefit corporation on February 1, 2021, with directors required to balance stockholder interests, stakeholder interests, and its stated public benefit purpose.
- Veeva had a $13.1M remaining minimum purchase commitment to Salesforce through September 1, 2025. Its securities portfolio is exposed to interest-rate movements; a modeled 100-basis-point increase would have reduced portfolio market value by $13M as of July 31, 2021.
Important facts for investors to verify
- Whether Vault’s faster growth continues and how product mix affects subscription growth and margins.
- Subsequent-quarter cash generation, given seasonality and management’s warning of lower operating cash flow later in FY2022.
- Effects of higher hiring, compensation, and stock-based compensation on operating margins.
- Developments and potential financial consequences in the IQVIA and Medidata litigation.
- Whether customer and industry changes, including possible sales-representative reductions, affect Commercial Cloud renewals and expansion.
- Progress against the $1.197B subscription performance-obligation balance and its expected recognition schedule.